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Abstract: 5-HT
1A autoreceptor antagonists enhance the
effects of antidepressants by preventing a negative feed-
back of serotonin (5-HT) at somatodendritic level. The
maximal elevations of extracellularconcentration of 5-HT
(5HText) induced by the 5-HT uptake inhibitor paroxetine
in forebrain were potentiated by the 5-HT1A antagonist
WAY-100635 (1 mg/kg s.c.) in a regionally dependent
manner (striatum > frontal cortex > dorsal hippocam-
pus). Paroxetine (3 mg/kg s.c.) decreased forebrain 5-
Hlext during local blockade of uptake. This reduction was
greater in striatum and frontal cortex than in dorsal hippo-
campus and was counteracted by the local and systemic
administration of WAY-100635. The perfusion of 50
pmol/L citalopram in the dorsal or median raphe nucleus
reduced 5HText in frontal cortex or dorsal hippocampus
to 40 and 65% of baseline, respectively. The reduction
of cortical 5HText induced by perfusion of citalopram in
midbrain raphe was fully reversed by WAY-100635 (1
mg/kg s.c.). Together, these data suggest that dorsal
raphe neurons projecting to striatum and frontal cortex
are more sensitive to self-inhibition mediated by 5-HT1A
autoreceptors than median raphe neurons projecting to
the hippocampus. Therefore, potentiation by 5-HT1A an-
tagonists occurs preferentially in forebrain areas inner-
vated by serotonergic neurons of the dorsal raphe
nucleus. Key Words: 5-HT1A receptor antagonist—5-
Hydroxytryptamine (serotonin) —5-Hydroxytryptamine
uptake inhibitors—Dorsal raphe nucleus—Median raphe
nucleus—Paroxetine.
J. Neurochem. 68, 2593—2603 (1997).
The treatment of major depression with selective
serotonin F 5-hydroxytryptamine (5-HT)] reuptake in-
hibitors (SSRIs) is effective in less than two-thirds of
patients. SSRIs selectively block the 5-HT transporter
(Hyttel, 1994), and therefore their clinical actions
likely derive from an enhancement of serotonergic
transmission. Yet, clinical improvement requires pro-
longed treatments despite the capacity of SSRIs to
block the 5-HT transporter rapidly. Neurochemical
studies have shown that 5-HT uptake inhibitors in-
crease the extracellular concentration of 5-HT (5-
HText) in the midbrain raphe nuclei (Adell and Artigas,
1991; Fuller, 1994; Gardier et al., 1996), which consti-
tute the main source of forebrain serotonergic innerva-
tion (Dahlström and Fuxe, 1964). The excess 5-HT~~1
in the midbrain raphe activates somatodendritic autore-
ceptors and reduces 5-HT release in forebrain (Adell
and Artigas, 1991; Rutter and Auerbach, 1993; Romero
et al., 1994). As a result, single treatment with clini-
cally relevant doses of SSRIs causes little or no in-
crease of 5-HT~~~in forebrain (Bel and Artigas, 1992;
Invernizzi et al., 1992; Gartside et al., 1995; Malagié
et al., 1996). Because the forebrain 5-HT release de-
pends on nerve impulse, these observations are consis-
tent with the suppression of firing evoked by antide-
pressants in 5-HT neurons of the dorsal raphe nucleus
(Aghajanian et al., 1970; Scuvée-Moreau and Dresse,
1979; Blier and de Montigny, 1994).
It was thus hypothesized that addition of 5-HT A
antagonists could enhance the antidepressant effects of
SSRIs by preventing this negative feedback (Artigas,
1993). Two pilot studies using pindolol (a nonselec-
tive ~-adrenoceptor/5-HTlA antagonist) have reported
results consistent with this hypothesis (Artigas et al.,
1994a; Blier and Bergeron, 1995), which has received
further confirmation in a controlled trial (V. Pérez et
al., manuscript in preparation). (— )-Pïndolol prevents
the self-inhibition of dorsal raphe serotonergic neurons
produced by the SSRIs and therefore potentiates their
effects in various brain areas (Artigas et al., 1994b;
Dreshfield et al., 1996; Romero et al., 1996).
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Serotonergic neurons of thedorsal and median raphe
nuclei innervate different forebrain territories (Azmitia
and Segal, 1978). The activation of 5-HTtA autorecep-
tors by selective agonists has been reported to cause
a greater reduction of activity in 5-HT neurons of the
dorsal raphe nucleus (Sinton and Fallon, 1988; Blier
et al., 1990) and of 5-HT synthesis and release from
the corresponding axon terminals (Invernizzi et al.,
1991; Casanovas and Artigas, 1996). However, such
a differential sensitivity has not been found by others
(Hjorth and Sharp, 1991; Hajos et al., 1995), and
therefore it is not firmly established whether 5-HT re-
lease is equally inhibited by SSRIs in dorsal and me-
dian raphe tracts. Using microdialysis in awake rats,
we have assessed the role of somatodendritic 5-HT1 A
autoreceptors in the potentiation of SSRI effects by 5-
HTIA antagonists and the putative differential sensitiv-
ity of dorsal and median raphe neurons to self-inhibi-
tion after treatments with SSRIs.
MATERIALS AND METHODS
Animals
Male Wistar rats (Iffa Credo, Lyon, France) weighing
280—320 g were used. Animals were kept in a controlled
environment (12-h light—dark cycle and 22 ± 2°C room
temperature). Food and water were provided ad libitum.
Animal care followed the European Union regulations (O.J.
of E.C. L358/l 18/12/1986).
Drugs and reagents
5-HT was from Research Biochemicals International (Na-
tick, MA, U.S.A.). The SSRIs citalopram HBr and paroxe-
tine HCI were generously provided by Lundbeck and Smith
Kline Beecham, respectively. WAY-l00135 { (S)-N-tert-
butyl -3- [4- (2- methoxyphenyl )piperazin - I - yl I -2-phenyl -
propanamide } (Cliffe et al., 1993), WAY-l00635 {N-[2-
[4-(2-methoxyphenyl)- 1 -piperazinyl]ethyl]-N-(2-pyri-
dyl )cyclohexanecarboxamide 3HC1 } (Fletcher et al., 1995),
and [
3H]WAY-100635 (sp cific activity, 80 Ci/mmol) were
generously supplied by Wyeth Ayerst. Other materials and
reagents were from local commercial sources. Drugs were
injected intraperitoneally or subcutaneously at the doses indi-
cated (base form; 1—2 mI/kg) or dissolved in the microdial-
ysis perfusion fluid for local applications by reverse dialysis.
Neither citalopram nor WAY-l00635 altered substantially
the pH of the artificial CSF used to perfuse the probes.
Microdialysis experiments
Four different sets of experiments were performed to ex-
amine the role of somatodendritic 5-HT A autoreceptors in
the control of 5-HT release during the local or systemic
treatment with SSRIs. First, the effects of paroxetine, alone
or in combination with WAY-100635 (1 mg/kg, s.c.), on
5-HT~X were examined in four forebrain areas (striatum,
frontal cortex, ventral hippocampus, and dorsal hippocam-
pus) differentially innervated by serotonergic neurons of the
dorsal and median raphe nuclei (Azmitia and Segal, 1978).
Animals were randomly allocated to receive either paroxet-
inc plus saline or paroxetine plus WAY-100635. Second,
WAY-100635 (100 ~imol/L) was administered through 1.5-
mm-long probes located in the dorsal raphe nucleus (Ferré
et al., 1994) during the systemic treatment with paroxetine
to examine the involvement of sornatodendritic 5-HT
1,~aut-
oreceptors. Pilot experiments revealed that lower concentra-
tions ofWAY-100635 (I and 10 ~imol/L) did not attenuate
the reduction of cortical 5-HT release induced by application
of citalopram in the dorsal raphe nucleus. A third group of
experiments was performed, based on the observation that
the systemic administration of an SSRI resulted in a reduc-
tion of 5-HT release in the dicncephalon and hippocampus
when the 5-HT transporter was blocked in these areas by
the local infusion of a SSRI using reverse dialysis (Rutter
and Auerbach, 1993; Hjorth and Auerbach. 1994). This re-
duction results from the activation of somatodendritic 5-
HTIA autoreceptors by the excess 5-HT~~in the interstitial
space outside the cell bodies produced by 5-HT uptake
blockers (Adell and Artigas, 1991: Bel and Artigas, 1992;
Invernizzi et al., 1992; Gartside et al., 1995; Malagié et al.,
1996). WAY-100635 was then locally (in the dorsal raphe
nucleus) or systemically administered to examine its effects
on 5-HTCS~in frontal cortex. Animals were randomly im-
planted with probes in striatum and dorsal hippocampus.
Finally, the fourth set of experiments included the local acti-
vation of somatodendritic 5-HT1,5 receptors in the dorsal or
median raphe nucleus [using 1.5-mm-long probes (Ferré et
al., 1994)] or in the dorsal plus median raphe nuclei [using
4-mm-long probes, 0.5 mm away from the midline (Adell
and Artigas, 199lfl by the local application of the SSRI
citalopram in rats with dual probe implants (dorsal raphe—
striatum; median raphe—dorsal hippocampus). The blockade
of the 5-HT uptake increases 5-HT~~5in the midbrain raphe
and reduces 5-HT release in frontal cortex (Adell and Arti-
gas, 1991) and striatum (Romero et al., 1994, 1996). 5-
HTA antagonists were then systemically administered to
assess their effects on the reduction of terminal 5-HT release
induced by citalopram.
Anesthetized rats (pentobarbital, 60 mg/kg i.p.) were im-
planted stereotaxically with 0.25-mm-od., concentric dial-
ysis probes (Adell and Artigas, 1991) in the different brain
areas (Table I). Microdialysis experiments were conducted
~-20 h after probe implants in conscious, freely moving
animals. Animals were implanted with one or two microdial-
ysis probes in the regions of interest, as required by the
experimental model used. In one experiment, citalopram was
infused into the dorsal raphe nucleus through a metal tube
at 0.05 ~zl/min (Romero et al., 1994) instead of being deliv-
ered by reverse dialysis. Both procedures induced equivalent
reductions of 5-HT release in striaturn or frontal cortex.
Probes were perfused with artificial CSF (125 mM NaCI,
2.5 mM KCI, 1.26mM CaC12, and 1.18mM MgCL) at 0.25
~d/min. Under these conditions, the in vitro recovery of the
dialysis probes for 5-HT was 27 ± 2 (1.5 mm) and 42
±1% (4 mm). Sample collection started 60 min after the
beginning of perfusion. Usually four or five fractions were
collected to obtain basal values before either local infusion
or systemic administration of drugs. Successive 20-min dial-
ysate samples were collected. Because of the marked reduc-
tion of cortical and striatal 5-HT release elicited by the local
infusion of citalopram in the somatodendritic area (Romero
et al., 1994, 1996), probes of the animals of the fourth
experimental group were perfused with artificial CSF con-
taining 1 ~smol/L citalopram. This enhanced the detectability
of 5-HT and reduced the variability of the measures without
affecting the experimental model, i.e., control of terminal
release through the activation of somatodendritic 5-HT1,5 by
5-HT. Similarly, cortical probes of the animals of the third
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TABLE 1. Length of microdialysis probes and stereotaxic coordinates ~t implants
Region
Length
(mm) AP DV L
Vertical
angle
Dorsal raphe nucleus 1.5 —7.8 —7.5“ —3.1 30°
Median raphe nucleus 1.5 —7.8 —8.9° —2.0 13°
Dorsal plus median raphe nuclei 4.0 —7.8 —9.0 —0.5 0°
Dorsal hippocampus 1.5 —3.8 —4.0 —1.8 0°
Ventral hippocampus 4.0 —5.8 —8.0 —5.0 00
Dorsal striatum 4.0
1.5
0.2
0.2
—8.0
—6.1
—3.0
—3.0
00
00
Frontal cortex 4.0 3.4 —6.0 —2.5 00
Coot‘dinates (AP, DV, and L) are given in mm, with respect to bregma and dura mater according to the
rat brain atlas of Paxinos and Watson (1986).
“The dorsoventral coordinate corresponds to the actual descent of the probe along a line inclined 13 or
30°with respecl to the vertical.
group were perfused with 1 pmol/L citalopram, as required
in this experimental model (Rutter and Auerbach, 1993;
I ljorth and Auerbach, 1994).
Chromatographic analysis
5-HT was analyzed by a modificationof an HPLC method
previouslydescribed (Adell and Artigas, 1991). Thecompo-
sition of HPLC eluant was as follows: 0.15 M NaH2PO4,
1.3 mM octyl sodium sulfate, 0.2 mM EDTA (pH 2.8 ad-
justed with phosphoric acid), pILls 27% methanol. 5-HT was
separated on a 3-pm (particle size) ODS 2 column (7.5
>< 0.46 cm; Beckman) and detected amperometrically with
a Hewlett Packard model 1049 detector (oxidation potential,
f t).6 V). Retention time was 3.5—4 min. The detection
Inuit l‘or 5—HT was 0.5—l fmol.
In vivo labeling of 5-HTIA receptors by
I ~HI WAY-100635
The extent of the diffusion of WAY-100635 in the mid-
brain raphe area after its local application in the dorsal raphe
nucleus by reverse dialysis was determined using
I il lj WAY-I 00635. Dialysis probes (1.5 mm long) were
placed in the dorsal raphe nucleus and perfused (0.25 p1/
miii) with artilicial CSF containing 100 pmol/L WAY-
100635 (plus 100 nmol/L radioactive tracer). The in vitro
recovery of the dialysis probes (1.5 mm) for WAY-100635
was calculated from the radioactivity counts in equivalent
volitmes of the artificial CSF at the probe inlet and outlet
during the infusion of flHjWAY-100635 plus WAY-
100635. This was found to he 58.7 ±4.6% (n = 4). After
nit inILtsion period of 1.2 h. the rats were decapitated, and
lic brains wei~eremoved and frozen. Coronal midbrain sec-
tions (14 pm thick) were cut to examine the in vivo labeling
ni dorsal raphe nucleus 5-HTIA receptors by [
3HiWAY-
1)0635 (Laporte et a ., 1994; Gozlan et al., 1995; Khawajaet
tI., 1995). Given the rostrocaudal distribution of the various
neuronal groups composing the dorsal raphenucleus, coronal
sections were cut at different anteroposterior levels (approxi-
ittately froin —6.5 to —-9.0mm relative to bregma). Sections
:tt hippocampal and cortical levels were also cut to examine
whether 5-HTIA receptors in these areas (Marcinkiewicz et
aI.. 1984; Pazos and Palacios, 1985; Pompeiano et al., 1992)
were also labeled by infusion of [3H]WAY-100635. The
scclions were exposed to a tritium-sensitive film (Hyperfilm-
‘li; Aniershani, U.K.) for 3 weeks. The optical density of
lIte tritium labeling in films was measured using an image
analysis system (Imaging Research, St. Catharines, Ontario,
Canada). The surface of areas showing a dense labeling
by [3H]WAY-l00635 was quantified to calculate the total
amount of tritium label in each section.
Data analysis
Microdialysis results are expressed as femtomoles per
fraction (uncorrected for recovery) and represented as per-
centages of basal values (individual means of four predrug
fractions) to facilitate comparisons between the different
experimental groups. Statistical analysis of single drug ef-
fects has been performed using ANOVA for repeated-mea-
sures and paired t tests of raw data. Two-way ANOVA de-
signs were used to examine the interaction between 5-HT
1,5
antagonists and SSRIs or regional effects. ANOVA of area-
under-the-curve (AUC) data was also used to examine the
dose and region factors on dialysate 5-HT after thetreatment
with paroxetine. Autoradiographic data are expressed as
femtomoles of [
3H]WAY-100635 per section. Data are
given as mean ±SEM values. Statistical significance has
been set at the 95% confidence level (two tailed).
RESULTS
Increase of 5-HT~~
1in forebrain by paroxetine
Table 2 shows the basal values of dialysate 5-HT
(with and without I ~.tmol/L citalopram in the perfu-
sion fluid) in the different brain regions examined. The
intraperitoneal administration of 3 mg/kg paroxetine
significantly increased dialysate 5-HT levels in four
forebrain areas differentially innervated by the dorsal
and median raphe nuclei (striatum, frontal cortex,
ventral hippocampus, and dorsal hippocampus) (p
<0.001 by repeated-measures ANOVA). Minimal
and maximal elevations of dialysate 5-HT in the differ-
ent regions were 231 and 289% of basal values (AUCs
of 160 min postparoxetine) in dorsal hippocampus and
striatum, respectively (Fig. 1). These elevations were
not significantly different (one-way ANOVA). The
increment of the paroxetine dose to 10 mg/kg did not
elevate further dialysate 5-HT levels in frontal cortex
(p < 0.001 for effect of paroxetine treatment; nonsig-
nificant effect of the dose by two-way ANOVA). By
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TABLE 2. Basal concentration values of dialy.cate 5-HT
Citalopram
concentration
in dialysis fluid Region
5-HT00 (fmol/
fraction)
None FC (4 mm)
STR (4 mm)
VHPC (4 mm)
DHPC (1.5 mm)
DRN (1.5 mm)
MRN (1.5 mm)
RN (4 mm)
2.2 ±0.1 (41)
2.9 ±0.4 (24)
3.8 ±(1.6 (lU)
2.0 ±0.2 (17)
11.2 ±4.3 (5)
7.3 ± .45 (8)
33.0 ± 11.9 (6)
I pmol/L DHPC (1.5 mm)
FC (4 mm)
STR (4mm)
STR (1.5 mm)
7.5 ±t).8 (12)
17.3 ± 1.5 (22)
17.5 ± 1.3 (17)
11.6 ± 1.6 (6)
Data are mean ±SEM values (no. of rats). DHPC, dorsal hippo-
campus; DRN. dorsal raphe nucleus; FC, frontal cortex; MRN, me-
dian raphe nucleus: RN, raphe nuclei (DRN + MRN); STR. dorsal
striatum; VHPC, ventral hippocampus.
contrast, 10 mg/kg elicited a somewhat larger incre-
ment of 5-HT001 in ventral hippocampus, which was
significantly different from that produced by 3 mg/kg,
particularly at short times after paroxetine administra-
tion (p < 0.001, significant effects of the treatment
and the dose factors; Fig. 2).
Potentiation of paroxetine effects on 5-HT~~1by
WAY-100635
The systemic administration of WAY-100635 (I mg/
kg s.c.) to saline-pretreated rats did not modify 5-HT~01
in frontal cortex, striatum, or dorsal hippocampus (AN-
OVA for repeated measures) (Fig. 3). However, its
administration caused dramatic elevations of 5-HT00 in
the striatum and frontal cortex of rats pretreated with 3
mg/kg i.p. paroxetine (Fig. 3;p <0.001 in all cases by
repeated-measures ANOVA). Dialysate 5-HT content
increased to 670% of basal values in frontal cortex and
FIG. 1. Effect of systemic administration of the SSRI paroxetine
(3 mg/kg, i.p.) on extracellular 5-HT in forebrainareas differentially
innervated by serotonergic neurons of the dorsal or median raphe
nucleus. FC, frontal cortex; STR, dorsal striatum; VHPC, ventral
hippocampus; DHPC, dorsal hippocampus. Ordinates are AUCs
of posttreatment values (160 mm), expressed as percentages of
the relative basal values in each brain area. Theeffects ofparoxet-
me were statistically significant in all cases (p < 0.001 by ANOVA
for repeated measures) without significant differences between
regions (one-way ANOVA). Data are mean ±SEM (bars) values
(n = 4 animals in DHPC, 6 animals in VHPC, 13 animals in STR,
and 18 animals in FC) (the data for STR and FC have been pooled
from two and three different experimental groups with no signifi-
cant differences between them).
FIG. 2. Changes of dialysate 5-HT in frontal cortex (FC) and
ventral hippocampus (VHPC) after two different doses of paro-
xetine [3 (•) and 10 mg/kg (•)]. Injection is shown by an arrow.
Data are mean ±SEM (bars) values from four to six rats per
group except for 10 mg/kg paroxetine in VHPC (n = 12, pooled
from two different experiments). See text for statistical details.
to almost 1,800% in the striatum. The effect in dorsal
hippocampus was less marked (see Fig. 3, lower panel).
The maximal potentiation of paroxetine effects was
noted 40 min after administration of WAY-l00635 in
all brain areas. A two-way ANOVA of the AUC values
during the period of maximal potentiation (four frac-
tions) after the injection of WAY- 100635 or saline re-
vealed significant effects of the treatment and region
factors (p < 0.001 in both cases) and a significant
interaction (p < 0.027) of both factors.
To assess the participation of somatodendritic 5-
HTIA receptors in the potentiation of the paroxetine-
induced 5-HT elevations after the systemic treatment
with WAY-l00635, we examined the effects of its
local application in the dorsal raphe nucleus (100
~imol/L for 160 min at 0.25 ‚uI/mm; total amount de-
livered was 2.35 nmol taking into account the yield
of the dialysis membrane; 14.7 pmol/min) during the
administration of paroxetine. The infusion of WAY-
100635 in the dorsal raphe nucleus rapidly and signifi-
cantly increased dialysate 5-HT values in frontal cortex
of rats pretreated with 3 mg/kg paroxetine and re-
mained elevated for the rest of the infusion period (p
<0.01 vs. paroxetine alone by Student‘ s t test of AUCs
during perfusion time; p < 0.004 by repeated-measures
ANOVA vs. pre-WAY-100635 value; Fig. 4).
Actions of 5-HT at dorsal and median raphe
5-HT1A receptors: Antagonism by WAY-100635
Somatodendritic 5-HT A receptors were activated by
5-HT after the local or systemic administration of the
J. Nc‘urochenc., Vol. 68, No. 6, /997
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FIG. 3. Effect of administration of WAY-100635 (1 mg/kg, s.c.)
or saline 80 min after administration of paroxetine (3 mg/kg i.p.)
on dialysate 5-HT in dorsal striatum (STR), frontal cortex (FC),
and dorsal hippocampus (DHPC). First and second arrows de-
note injections of paroxetine (or saline) and WAY-100635 (or
saline), respectively. Data are mean ±SEM (bars)values. Exper-
imental groups were as follows: saline + WAY-100635 (O; n
4, 4, and 5, respectively), paroxetine + saline (•; n = 4, 6,
and 4), and paroxetine + WAY-100635 (A; n = 7, 9, and 8,
respectively). Note the different scales used along the y-axes.
Seetext for statistical details.
SSRIs citalopram and paroxetine, respectively. It was
reasoned that the reduction of terminal 5-HT release
would be attenuated by 5-HT IA autoreceptor antago-
lusts. Two sets of experiments were conducted. In the
first one, dialysis probes implanted in frontal cortex
weie perfused with artificial CSF containing 1 ‚umol/
L citalopram, thus locally blocking 5-HT reuptake into
nerve terminals. The intraperitoneal administration of
FIG. 4. Potentiation of the effect of paroxetine (3 mg/kg i.p.;
arrow) on dialysate 5-HT in frontal cortex by local application of
WAY-100635 in the DRN (100 pmol/L; cross-hatched horizontal
bar). Data are mean ± SEM (bars) values from five rats. The
dotted line indicates the effects of paroxetine alone (3 mg/kg
i.p.) in a separate group of animals (n = 6).
FIG. 5. Upper panel: Reduction of 5-HT release in frontal cortex
induced by systemic administration of paroxetine (3 mg/kg; U)
in conditions of local blockade ofthe uptake by 1 gmol/L citalo-
pram. Injection of paroxetine is shown by an arrow. The applica-
tion of WAY-100635 (100 pmol/L; shown by a horizontal cross-
hatched bar) partially counteracted the reduction induced by
paroxetine (A). Lower panel: Differential reduction of 5-HT re-
lease in dorsal striatum (•; n = 6) and dorsal hippocampus (•;
n = 4) by administration of 3 mg/kg paroxetine (first arrow)
in conditions of local blockade of the uptake with 1 pmol/L
citalopram. The injection of 1 mg/kg WAY-100635 (second
arrow) reversed the reduction induced by paroxetine and in-
duced an additional significant increment of 5-HT level. Data are
mean ±SEM (bars) values. Seetext for statistical analysis.
3 mg/kg paroxetine induced a sustained reduction of
cortical dialysate 5-HT to 40% of predrug values. e.g.,
from 16.5 ±3.8 to 6.8 ±1.6 fmol per fraction, that
was statistically significant (p < 0.001; Fig. 5, upper
panel). The application of WAY-100635 (100 ‚umol/
L) in the dorsal raphe nucleus partially antagonized the
paroxetine-induced reduction of dialysate 5-HT level
(significant effects of WAY-100635,p < 0.02 by Stu-
dent‘s t test of AUCs vs. paroxetine alone during perfu-
sion time; p < 0.001 by repeated-measures ANOVA
vs. pre-WAY-100635 values).
We further assessed the ability of paroxetine to re-
duce 5-HT in dialysates from dorsal striatum and dor-
sal hippocampus, two areas innervated in apreferential
manner by serotonergic axons originating in the dorsal
and median raphe nucleus, respectively. To exclude
any methodological source of possible differences, the
size of the microdialysis probes was the same (1.5
mm) in dorsal hippocampus and striaturn. The adminis-
tration of 3 mg/kg paroxetine significantly reduced 5-
HT content in both areas, although to a greater extent
in the striatum (p < 0.0001, significant effect of the
treatment; p < 0.0001, significant treatment X region
interaction; Fig. 5, lower panel). The reduction of 5-
HT release was counteracted by systemic administra-
tionof 1 mg/kg WAY-100635 (p <0.001 by repeated-
measures ANOVA) in both regions. WAY-100635
caused 5-HT values to increase above pretreatment
levels. This is likely due to additional blockade of the
J. Nc‘uroc/ic‘nc., t‘ccl, 6$‘, No 6 /997
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FIG. 6. Attenuation of 5-HT release in frontal cortex (FC) and
dorsal hippocampus (DHPC) during infusion of citalopram (50
pmol/L; open bar) in the dorsal raphe nucleus (DRN; n = 5) and
median raphe nucleus (MRN; n = 8), respectively, using 1.5-
mm-long dialysis probes (see Table 1 for coordinates). Dataare
mean ±SEM (bars) values. Upper panel: Citalopram caused a
rapid and sustained elevation of 5~HTextin the DRN (•) and
MRN (LII). Lower panel: The 5~HTextconcentration in FC (U)
and DHPC (O) was reduced during citalopram infusion in DRN
and MRN, respectively, to —40 and 65% of pretreatment values.
See text for statistical details.
transporter by the systemic administration of paroxet-
inc plus the prevention of the self-inhibition by WAY-
100635.
In a second set of experiments, citalopram (50
pmol/L) was infused through 1.5-mm dialysis probes
in the dorsal or median raphe of animals implanted
with a second probe in frontal cortex or dorsal hippo-
campus, respectively. Application of citalopram in the
dorsal raphe nucleus caused a rapid and sustained ele-
vation of dialysate 5-HT, which was followed by a
very marked reduction of the 5-HT output in frontal
cortex (p < 0.001 for both regions by repeated-mea-
sures ANOVA; Fig. 6). Similarly, the application of
the same citalopram concentration in the median raphe
nucleus caused a very large increase in 5-HT content
(maximal increase to 15-fold of baseline) that was
also accompanied by a reduction of the 5-HT output
in dorsal hippocampus (p < 0.001 for both regions by
repeated-measures ANOVA; Fig. 6, lower panel). A
two-way analysis of the data also revealed a significant
treatment X region interaction (p < 0.001).
When citalopram was infused through a vertical
probe (4 mm long, 0.5 mm away from the midline) in
the vicinity of both midbrain raphe nuclei, a somewhat
smaller but still very marked enhancement of dialysate
5-HT in the midbrain was observed (p < 0.001 by
repeated-measures ANOVA; Fig. 7, upper panel). This
was accompanied by adecline of dialysate 5-HT values
in frontal cortex to 55% of basal levels (p < 0.001;
Fig. 7, lower panel). The injection of 1 mg/kg WAY-
100635 fully reversed the attenuation of cortical 5-HT
release caused by citalopram (p <0.001 vs. pre-WAY-
100635 values by Student‘s t test) and further in-
creased dialysate 5-HT content in raphe to ‚~ 1,900%
of basal levels (p <0.035 vs. pre-WAY-l00635 values
by paired Student‘ s t test; Fig. 7). The blockade of 5-
HT A receptors by WAY- 100635 was reversible, as 2
h after its administration cortical and raphe dialysate
5-HT values had almost returned to pre-WAY-l00635
values, while citalopram was still being infused in the
midbrain raphe.
The infusion of 50 ‚umol/L citalopram in the dorsal
raphe nucleus caused a marked reduction of striatal 5-
HT release that was not counteracted by the 5-HTIA
antagonist WAY-100l35 at 10 mg/kg (significant ef-
fects of citalopram, p < 0.001 in both cases; nonsig-
nificant effect of the pretreatment with WAY- 100135;
Fig. 8).
Autoradiographic analysis of distribution of
[3H]WAY-100635 in rat brain after local
application in dorsal raphe nucleus
To examine the involvement of somatodendritic and
postsynaptic 5-HT A receptors in the action of locally
applied WAY-100635, we perfused 100 pmol/L
WAY-100635 plus 100 nmol/L [3H]WAY-100635
into the dorsal raphe nucleus, using the same experi-
mental conditions as in previous microdialysis experi-
ments, except for the infusion time, which was reduced
to half (1 h 20 mm). At this time, WAY-l00635 had
already exerted its full antagonistic effects (see Figs.
FIG. 7. Upper panel: Increase of dialysate 5-HT content in the
vicinity of the dorsal and median raphe nuclei (RN) after local
application of citalopram (open bar) throughavertical microdial-
ysis probe (4 mm long, 0.25 mm o.d.; 0.5 mm away from the
midline). Administration of WAY-100635 (1 mg/kg s.c.; arrow)
induced an additional increase of 5-HT content up to -1,800%
of precitalopram values. Lower panel: Attenuation of the 5-HT
release in frontal cortex (FC) by local application of citalopram
in the raphe nuclei. The period of infusion is shown by an open
bar. Systemic administration of WAY-100635 (1 mg/kg s.c.)
completely reversed the reduction of 5-HT release induced by
citalopram, although the effect was transient due to the short
half-life of this compound. Data are mean ±SEM (bars) values
from six rats. See text for statistical details.
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FIG. 8. Attenuation of striatal 5-HT release by application of
citalopram (50 pmol/L) in the dorsal raphe nucleus (open bar).
Arrow denotes the subcutaneous injection of saline (U) or 10
mg/kg WAY-i 00135 (7). Two-way ANOVA did not reveal a sig-
nificant effect of WAY-i00135. Data are mean ±SEM (bars)
values from six or seven rats. For comparison, the antagonistic
effects of 15 mg/kg (—)-pmndolol using the same experimental
procedure are shown (dotted line). Data for pindolol are from
Romero et al. (1996).
4 and 5), and therefore the infusion for additional
time was not considered necessary, thus helping to
minimize the amount of radioactivity used. Autoradio-
graphic analysis showed that the radioactive label was
distributed along the anteroposterior axis at the dorsal
raphe level, with greater amounts in central regions
(Fig. 9). Neither the neighbor median raphe nucleus
nor more distant areas rich in postsynaptic 5-HT A
receptors, like the hippocampus or frontal cortex,
showed any sign of labeling by [3H]WAY-100635(Fig. 10).
DISCUSSION
The serotonergic system is involved in many brain
functions, such as motor control, cognition, process of
sensory information, and mood regulation (Jacobs and
Azmitia, 1992; Jacobs and Fornal, 1993; Maes and
Meltzer, 1995). A relatively small number of cells in
the midbrain raphe nuclei innervates all forebrain areas
with a veryhigh density of nerve terminals (Descarries
et al., 1982; Oleskevich and Descarries, 1990; Jacobs
and Azmitia, 1992). Serotonergic neurons are ex-
tremely sensitive to self-inhibition by 5-HT (Aghajan-
ian et al., 1972; Haigler and Aghajanian, 1974). This
process is mediated by somatodendritic S-HT IA recep-
tors coupled through G
1/G0 proteins to a K~channel
(Aghajanian and Lakoski, 1984; Blier and de Mon-
tigny, 1987; Sprouse and Aghajanian, 1987; Innis et
al., 1988). Consequently, the activation of somatoden-
dritic S-HT IA receptors results in a widespread reduc-
tion of the electric and metabolic activity in ascending
serotonergic axons.
The SSRIs act as indirect S-HT IA agonists owing to
the excess S~HText produced by these agents in the
midbrain raphe. This activates somatodendritic S-HT IA
autoreceptors and limits the increment of SHText pro-
duced in forebrain. The present results indicate that
the maximal effects of the systemic administration of
paroxetine, a very potent SSRI (Thomas et al., 1987;
Hyttel, 1994), in various forebrain regions are limited
to a two- to threefold increment of S~HTex1(see, how-
ever, the large increment of S~HTextproduced in fore-
brain by the partial local blockade of the S-HT trans-
porter by 1 ‚umol/L citalopram in Table 2). Yet, the
subsequent administration of WAY-100635, a very se-
lective and potent S-HTIA antagonist (Fletcher et al.,
1995; Forster et al., 1995) counteracted the self-inhibi-
tion produced by paroxetine and markedly potentiated
the increase of S-HT~0~.In keeping with the present
results, several groups have reported the potentiation
of SSRI-induced forebrain increases of S-HT~01by se-
lective and nonselective S-HTIA antagonists (Inver-
nizzi et al., 1992, 1996; Hjorth, 1993; Artigas et al.,
1994b; Gartside et al., 1995; Arborelius et aI., 1996;
Dreshfleld et al., 1996; Romero et al., 1996). This
effect is likely mediated at somatodendritic level, as
the intraraphe or systemic application of 5-HT IA antag-
onists prevented the inhibition of cell firing and termi-
nal S-HT release elicited by the activation of somato-
dendritic S-HT IA receptors (Blier and de Montigny,
1994; Arborelius et al., 1995; Gartside et aI., 1995;
Romero et al., 1996; see also Fig. S).
Anatomical data indicate that the striatum and the
frontal cortex are innervated by 5-HT neurons of the
dorsal raphe nucleus in an exclusive and preferential
manner, respectively (Azmitia and Segal, 1978; 1mai
et al., 1986). In contrast, the dorsal hippocampus is
mostly innervated by S-HT neurons of the median ra-
phe nucleus. The preferential enhancement of S~HText
by WAY-l0063S in striatum and frontal cortex agrees
with previous data indicating a greater inhibition of
the activity of serotonergic neurons of the dorsal raphe
nucleus after systemic treatment with S-HTIA agonists
(Sinton and Fallon, 1988; Blier et al., 1990; Invernizzi
et al., 1991; Lésourd et al., 1995; Casanovas and Arti-
gas, 1996). It is unclear whether this is due to a differ-
FIG. 9. A: Autoradiograms of 10 coronal sections at equally
spaced anteroposterior levels of the midbrain (approximately
from —7.6 to —8.7 mm with respect to bregma) show intense
labeling of 5-HTIA receptors of the dorsal raphe nucleus by
[
3HIWAY-i00635.B: Bar hi togram shows the amo nt of the
radioactive tracer of the same sections. Abscissa shows the
coordinates (in mm) with respect to bregma.
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FIG. 10. A—C: Cresyl violet staining of rat brain coronal sections at frontal cortex (FCx; A), hippocampus (B), and midbrain (C) levels.
Superimposed on the latter is a schematic drawing of the location of microdialysis probes in the dorsal raphe nucleus (DRN). D—F:
Corresponding autoradiograms obtained after in vivo perfusion of [3HIWAY-100635 (see Materials and Methods) in the DRN. Notethe intense labeling of the DRN in F and its absence in the median raphe nucleus (MRN). Autoradiograms of cortical and hippocampal
sections (D and E) showed no signs of label by the radioactive tracer. The midbrain section corresponds approximately to bregma
—7.8. Bar = 2 mm. CA, Ammon‘s horn; DG, dentate gyrus.
ential reduction of cell firing at the cell body level by
these agents or whether local factors in projection areas
are involved, as recent data suggest an equal potency
of paroxetine to inhibit dorsal raphe and median raphe
neurons in anesthetized rats (Hajos et al., 1995). The
present observations indicate that the 5-HT release by
axon terminals of dorsal raphe neurons of the cortico-
striatal pathway is inhibited to a greater extent than
that in the median raphe-hippocampal tract. This is
supported by two different sets of experiments in
which 5-HT A receptors in the dorsal or median raphe
nucleus have been locally or systemically activated by
5-HT and is in full agreement with the greater potentia-
tion of paroxetine effects by WAY- 100635 in striatum
and frontal cortex (as compared with dorsal hippo-
campus).
The synergistic action of WAY-I 00635 most likely
results from the blockade of S-HTIA receptors, as it
prevents the suppression of cell firing induced by 8-
hydroxy-2-(di-n -propylamino) tetralin (Forster et al.,
1995). Serotonergic neurons of the dorsal raphe nu-
cleus also express 5-HTIB and 5-HTI) subtypes (for
review, see Hoyer et al., 1994), and 5-HT
10 receptors
may also behave as somatodendritic autoreceptors
(Pifleyro et al., 1995). However, the affinity of WAY-
100635 for 5-HTIB/ID receptors is much lower than
that for the 5-HT!A receptors (Forster et al., 1995),
and the cell firing of serotonergic neurons is not con-
trolled by 5-HT10 receptors (Sprouse and Aghajanian,
1987, 1988). These observations argue against the
involvement of other 5-HT receptor subtypes in the 5-
HT-enhancing action of WAY-100635.
The infusion of citaloprarn in the dorsal raphe nu-
cleus or in the vicinity of dorsal and median raphe
nuclei caused a marked reduction of 5-HT release in
frontal cortex, likely resulting from the activation of
somatodendritic 5-HTIA autoreceptors, as the systemic
administration of WAY-l00635 fully reversed the cor-
tical 5~HTexdecline and further increased the citalo-
pram-induced elevation of 5-HT00 in the raphe. The
latter observation clearly indicates that 5-HT release
in the dorsal and median raphe nuclei is also inhibited
by activation of somatodendritic 5-HT JA receptorsdur-
ing the treatment with SSRls. lt is unclear whether
there is a tonic inhibition of somatodendritic 5-HT
release in a physiological situation in the rat brain,
because WAY-I00635 did not elevate 5-HT005 in fore-
brain when administered alone. However, it moder-
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ately increased the firing rate of single units in the
dorsal raphe nucleus of the awake cat (Fornal et al.,
1996), thus suggesting a tonic control of serotonergic
cell firing by 5-HTtA receptors in this species during
periods of behavioral activation. The absence of a cor-
responding increment in the forebrain S-HT release in
rats may possibly be related to changes in the S-HT A
tone across the sleep—waking cycle, as the present
experiments were conducted during the period of low
behavioral activity, i.e., daytime.
The local application of WAY- 100635 in the dorsal
raphe nucleus potentiated the systemic effects of paro-
xetine in frontal cortex and partially counteracted the
reduction of cortical S-HT release induced by systemic
paroxetine when the 5-HT uptake was locally blocked
in frontal cortex. The conspicuous and selective label-
ing of the dorsal raphe nucleus by ~3H]WAY-l0063S
when locally infused indicated that only somatoden-
dritic S-HT IA receptors of this nucleus were involved.
However, WAY-10063S seemed to be more effective
at antagonizing the inhibitory effects of 5-HT at 5-
HTIA receptors after its systemic administration, which
may indicate either the involvement of postsynaptic
S-HTtA receptors in this effect or a more effective
antagonism after systemic administration. Indeed, the
activity of dorsal raphe neurons is controlled by fore-
brain afferents (Kalén and Wiklund, 1989; Kalén et
al., 1989; Behzadi et al., 1990; Levine and Jacobs,
1992; Peyron, 1996), and it has been suggested that
postsynaptic S-HT IA receptors may participate in the
reduction of the activity of dorsal raphe nucleus seroto-
nergic neurons by 5-HTIA agonists (Blier and de Mon-
tigny, 1987; Ceci et al., 1994; Romero et al., 1994).
Likewise, the hippocampal application of 5-HT IA ago-
nists reduced dorsal raphe nucleus neuronal firing, but
this effect may be perhaps mediated by diffusion via
CSF (Jolas et al., 1995). The present data fully support
that somatodendritic S-HT IA receptors participate in
the potentiation of paroxetine effects by WAY-10063S
but cannot fully exclude the involvement of postsynap-
tic S-HT IA receptors.
WAY- 100135 has been shown to prevent the reduc-
tion of terminal 5-HT release elicited by systemic ad-
ministration of 8-hydroxy -2- (di - n -propylaminotet-
ralin) or by moderate increments of 5~HText in the
dorsal raphe nucleus (Routledge et al., 1993; Ferré et
al., 1994; Hjorth and Auerbach, 1994). However, in
contrast to other mixed ß-adrenoceptor/S-HT A antag-
onists like (—)-tertatolol (Romero et aI., 1994) or
(—)-pindolol (Romero et al., 1996), WAY-100l35
did not prevent the reduction of striatal S-HT release
induced by local application of citalopram in the dorsal
raphe nucleus, a procedure causing a massive activa-
tion of S-HT IA autoreceptors by S-HT (see Figs. 6 and
7). The lesser ability of WAY-l00135 to antagonize
self-inhibitory effects in the dorsal raphe nucleus sug-
gests that this compound may be far less effective than
its congener WAY- 100635 in potentiating the actions
of SSRIs. Also, WAY-100635 increased and WAY-
100135 decreased S-HT cell firing in the awake cat
(Fornal et aI., 1996), a finding possibly related to the
at-adrenolytic properties of the latter (Lanfumey et
al., 1993).
In summary, the present study supports the con-
tention that selective 5-HT lA autoreceptor antagonists
may augment the clinical effects of SSRIs by increas-
ing serotonergic transmission more than the latter
alone. This effect takes place preferentially in forebrain
areas with selective or preferential innervation from
the dorsal raphe nucleus, e.g., cortex and striatum,
rather than those mainly innervated by the median ra-
phe nucleus (dorsal hippocampus). These observa-
tions are important to clarify the relative role of seroto-
nergic transmission in motor, limbic, and cortical areas
during the recovery from depression. Also, the involve-
ment of somatodendritic S-HT A receptors in the 5-
HT-enhancing effects of S-HT IA antagonists has been
extensively demonstrated.
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